European Group for Bone and Marrow Transplantation (EBMT)

Resolution of serious vaso-occlusive pain crises: results from the ongoing phase 1/2 HGB-206 Group C study of LentiGlobin for sickle cell disease (bb1111) gene therapy.

Authors: Mapara MY.